It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled ‘Long-term efficacy of tildrakizumab in European patients with moderate-to-severe plaque psoriasis from the 5-year reSURFACE 2 phase 3 trial‘ (P1754) at the EADV Virtual Congress, 29-31 October 2021.
Questions
- What is the rationale for the use of tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis? (0:08)
- Could you tell us a little about the reSURFACE 1 and reSURFACE 2 clinical studies and their findings? (0:26)
- What has the latest data taught us about the long-term efficacy and safety of tildrakizumab in this treatment setting? (1:05)
- How can we identify patients most likely to respond to tildrakizumab? (1:45)
- How does the efficacy and safety of tildrakizumab compare with other agents that also target IL-12, or specifically IL-17? (2:47)
Disclosures: Diamant Thaçi is a lecturer and/or consultant for AbbVie, Almirall, Amgen, Asana Biosciences, Biogen Idec, BIOCAD, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DS-Biopharma, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo Pharma, Eli Lilly, Novartis, Regeneron, Sandoz, Sanofi-Aventis and UCB, and received grants from AbbVie and Novartis (paid to institution).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
